Tag: 300-400

On May 1, 2007, Suga, Takeo; Pu, Yong-Jin; Kasatori, Shinji; Nishide, Hiroyuki published an article.Safety of 5-Bromo-2-iodobenzotrifluoride The title of the article was Cathode- and Anode-Active Poly(nitroxylstyrene)s for Rechargeable Batteries: p- and n-Type Redox Switching via Substituent Effects. And the article contained the following:

Three polystyrenes bearing redox-active nitroxide radical(s) in each repeating unit, poly[4-(N-tert-butyl-N-oxylamino)styrene] (1), poly[3,5-di(N-tert-butyl-N-oxylamino)styrene] (2), and poly[4-(N-tert-butyl-N-oxylamino)-3-trifluoromethylstyrene] (3), were synthesized via free radical polymerization of protected precursor styrenic derivatives and subsequent chem. oxidation The radicals in these polymers were robust at ambient conditions, and the polymers possessed radical densities of 2.97 脳 1021, 4.27 脳 1021, and 1.82 脳 1021 unpaired electrons/g for 1-3, resp., resulting in an electrode-active material with a high charge/discharge capacity. Particularly, the dinitroxide functional polymer 2 possessed the highest radical d. Cyclic voltammetry of the poly(nitroxylstyrene) 1 revealed a reversible redox at 0.74 V vs. Ag/AgCl, which was assigned to the oxidation of the nitroxide radical to form the oxoammonium cation (p-type doped state). However, the poly(nitroxylstyrene) ortho-substituted with the electron-withdrawing trifluoromethyl Group 3 showed a reversible redox at -0.76 V, ascribed to the n-type redox pair between the nitroxide radical and the aminoxy anion. Thus, the nitroxide radical polymer could be switched from p-type material suitable for a cathode to n-type material (anode-active) via altering the electron-withdrawing character of the substituents on the poly(nitroxylstyrene). This is the 1st report of an n-type radical polymer and the 1st report of using substituent effects to switch the redox behavior of the polymer. This versatile switching ability enables these polymers to function as components of metal-free electrodes in rechargeable batteries. The experimental process involved the reaction of 5-Bromo-2-iodobenzotrifluoride(cas: 364-12-5).Safety of 5-Bromo-2-iodobenzotrifluoride

The Article related to cathode anode poly nitroxylstyrene rechargeable battery switching redox, Electrochemical, Radiational, and Thermal Energy Technology: Energy-Conversion Devices and Their Components and other aspects.Safety of 5-Bromo-2-iodobenzotrifluoride

Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com

On December 13, 2018, Bartberger, Michael D.; Beck, Hilary Plake; Degraffenreid, Michael R.; Fox, Brian M.; Gonzalez Lopez De Turiso, Felix; Julian, Lisa D.; Kayser, Frank; Medina, Julio C.; Olson, Steven H.; Rew, Yosup; Roveto, Philip M.; Sun, Daqing; Yan, Xuelei published a patent.Electric Literature of 70931-59-8 The title of the patent was Preparation of cis-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer. And the patent contained the following:

The invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor. The title compounds [I; X = O or S(O)2; R1 = H, C1-6alkyl, (CReRe)nC6-8aryl, (CReRe)nC3-8cycloalkyl, (CReRe)n-3-8 membered heterocycloalkyl, S(O)2C3-8cycloalkyl, C(O)C3-8cycloalkyl, or CRfRa(CReRe)n-Q; Q = (CReRe)nC6-8aryl, (CReRe)n-3-8 membered heterocycloalkyl, (CReRe)n-5-8 membered heteroaryl, (CReRe)nC3-8cycloalkyl, cyano, (CReRe)nOH, CO2H, NReRe, etc.; R2 = H, C1-6alkyl, (CReRe)nC(O)ORe, (CReRe)nNReRe, (CReRe)nC(O)NReRe, (CReRe)nOH, (CReRe)nC(O)H, (CReRe)nC6-8aryl, (CReRe)n-3-8 membered heterocycloalkyl, (CReRe)n-5-8 membered heteroaryl, (CReRe)nCN, -(CReRe)nC(O)5-8 membered heterocycloalkyl, etc.; any heteroaryl or heterocycloalkyl group has one or more heteroatoms independently selected from O, N or S; any cycloalkyl, heterocycloalkyl, heteroaryl or aryl group can be unsubstituted or substituted; R3 = H or C1-6alkyl; R4 = C6-8 aryl or 5-9 membered heteroaryl; R5 = C6-8 aryl or 5-9 membered heteroaryl; R6, R7 = H or C1-6alkyl; Ra = independently H, C1-6alkyl, C2-6alkenyl, (CReRe)nC3-8cycloalkyl, or (CReRe)nC6-8aryl, wherein any cycloalkyl or aryl group can be unsubstituted or substituted; Re, Rf = independently H, C1-6alkyl , or OH; n, m = independently 0-4; provided that R2 and R3 are not both H] or pharmaceutically acceptable salts thereof were prepared These compounds including morpholinone and 2,5,6,8-tetrahydro-3H-imidazo[2,1-c][1,4]oxazine derivatives are inhibitors of MDM2 (oncoprotein) and are useful as therapeutic agents, particularly for the treatment of cancers. Thus, cyclocondensation of rel-(1R,2S)-1,2-bis(4-bromophenyl)-2-(methylamino)ethanol with 2-chloroacetyl chloride gave rel-(5R,6S)-5,6-bis(4-bromophenyl)-4-methylmorpholin-3-one which was treated with sodium bis(trimethylsilyl)amide followed by benzylation with benzyl bromide yo give rel-(2S,5R,6S)-2-benzyl-5,6-bis(4-bromophenyl)-4-methylmorpholin-3-one (II). II and 2-[rel-(2S,5R,6S)-4-benzyl-6-(3-chlorophenyl)-5-(4-chlorophenyl)-3-oxomorpholin-2-yl]acetic acid (III) showed IC50 of 1.96 and 0.0399 渭M, resp., for inhibiting the interaction of GST-hMDM2 and biotinylated-p53 in an homogeneous time-resolved fluorescence assay (HTRF1 assay). The experimental process involved the reaction of 1-(Bromomethyl)-4-fluoro-2-iodobenzene(cas: 70931-59-8).Electric Literature of 70931-59-8

The Article related to mdm2 oncoprotein inhibitor morpholinone tetrahydroimidazooxazine, morpholinone tetrahydroimidazooxazine preparation treatment cancer, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Electric Literature of 70931-59-8

Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com

On August 28, 2014, Bartberger, Michael D.; Beck, Hilary Plake; Degraffenreid, Michael R.; Fox, Brian M.; Gonzalez Lopez De Turiso, Felix; Julian, Lisa D.; Kayser, Frank; Medina, Julio C.; Olson, Steven H.; Rew, Yosup; Roveto, Philip M.; Sun, Daqing; Yan, Xuelei published a patent.Related Products of 70931-59-8 The title of the patent was Preparation of cis-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer. And the patent contained the following:

The title compounds [I; X = O or S(O)2; R1 = H, C1-6alkyl, (CReRe)nC6-8aryl, (CReRe)nC3-8cycloalkyl, (CReRe)n-3-8 membered heterocycloalkyl, S(O)2C3-8cycloalkyl, C(O)C3-8cycloalkyl, or CRfRa(CReRe)n-Q; Q = (CReRe)nC6-8aryl, (CReRe)n-3-8 membered heterocycloalkyl, (CReRe)n-5-8 membered heteroaryl, (CReRe)nC3-8cycloalkyl, cyano, (CReRe)nOH, CO2H, NReRe, etc.; R2 = H, C1-6alkyl, (CReRe)nC(O)ORe, (CReRe)nNReRe, (CReRe)nC(O)NReRe, (CReRe)nOH, (CReRe)nC(O)H, (CReRe)nC6-8aryl, (CReRe)n-3-8 membered heterocycloalkyl, (CReRe)n-5-8 membered heteroaryl, (CReRe)nCN, -(CReRe)nC(O)5-8 membered heterocycloalkyl, etc.; any heteroaryl or heterocycloalkyl group has one or more heteroatoms independently selected from O, N or S; any cycloalkyl, heterocycloalkyl, heteroaryl or aryl group can be unsubstituted or substituted; R3 = H or C1-6alkyl; R4 = C6-8 aryl or 5-9 membered heteroaryl; R5 = C6-8 aryl or 5-9 membered heteroaryl; R6, R7 = H or C1-6alkyl; Ra = independently H, C1-6alkyl, C2-6alkenyl, (CReRe)nC3-8cycloalkyl, or (CReRe)nC6-8aryl, wherein any cycloalkyl or aryl group can be unsubstituted or substituted; Re, Rf = independently H, C1-6alkyl , or OH; n, m = independently 0-4; provided that R2 and R3 are not both H] or pharmaceutically acceptable salts thereof were prepared These compounds including morpholinone and 2,5,6,8-tetrahydro-3H-imidazo[2,1-c][1,4]oxazine derivatives are inhibitors of MDM2 (oncoprotein) and are useful as therapeutic agents, particularly for the treatment of cancers. The cancer is selected from bladder, breast, colon, rectum, kidney, liver, small cell lung cancer, non-small-cell lung cancer, esophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, skin, acute lymphocytic leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, hairy cell lymphoma, Burkitt’s lymphoma, acute and chronic myelogenous leukemia, melanoma, endometrial cancer, head and neck cancer, glioblastoma, or osteosarcoma. Thus, cyclocondensation of rel-(1R,2S)-1,2-bis(4-bromophenyl)-2-(methylamino)ethanol with 2-chloroacetyl chloride in the presence of Et3N in THF at 0掳 for 1 h gave rel-(5R,6S)-5,6-Bis(4-bromophenyl)-4-methylmorpholin-3-one which was treated with sodium bis(trimethylsilyl)amide in THF at -78掳 for 20 min and then underwent benzylation with benzyl bromide at -78掳 for 30 min and at room temperature for 30 min to give rel-(2S,5R,6S)-2-benzyl-5,6-bis(4-bromophenyl)-4-methylmorpholin-3-one (II). II and 2-[rel-(2S,5R,6S)-4-benzyl-6-(3-chlorophenyl)-5-(4-chlorophenyl)-3-oxomorpholin-2-yl]acetic acid (III) showed IC50 of 1.96 and 0.0399 渭M, resp., for inhibiting the interaction of GST-hMDM2 and biotinylated-p53 in an homogeneous time-resolved fluorescence assay (HTRF1 assay). The experimental process involved the reaction of 1-(Bromomethyl)-4-fluoro-2-iodobenzene(cas: 70931-59-8).Related Products of 70931-59-8

The Article related to mdm2 oncoprotein inhibitor morpholinone tetrahydroimidazooxazine, morpholinone tetrahydroimidazooxazine preparation treatment cancer, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Related Products of 70931-59-8

Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com

On July 7, 2022, Jin, Jinghai; Shen, Chunli; Wu, Chengde; Chen, Shuhui published a patent.Recommanded Product: 364-12-5 The title of the patent was Preparation of selinexor analogs as XOP1 inhibitors. And the patent contained the following:

The invention relates to selinexor analogs (e.g., I) pharmaceutically acceptable salts thereof; pharmaceutical preparation comprising them; and their use as XOP1 inhibitors. The experimental process involved the reaction of 5-Bromo-2-iodobenzotrifluoride(cas: 364-12-5).Recommanded Product: 364-12-5

The Article related to selinexor analog antitumor xop1 inhibitor preparation, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Recommanded Product: 364-12-5

Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com

On March 26, 2015, Tokito, Shizuo; Kumaki, Daisuke; Mamada, Masashi; Fukuda, Kenjiro; Tanaka, Yasuhiro; Shima, Hidetaka; Yoneda, Yasuhiro; Fujita, Harunori; Kakita, Kazuaki; Omata, Youji; Yamada, Natsuko; Honma, Takashi; Machida, Toshikazu published a patent.Quality Control of 5-Bromo-2-iodobenzotrifluoride The title of the patent was Preparation of benzobis(thiadiazole) derivatives, ink containing them, and organic electronic device using them. And the patent contained the following:

The present invention pertains to a benzobis(thiadiazole) derivative represented by general formula [I; R1 = straight-chain or branched alkyl group or any of group A; group A = , NO2, F, Br, CF3, SCF3, C(R)F2, cyano, CO2R, Cl, iodo, OCF3, SF6, OC(R)F2, or OC(O)R, SC(R)F2; R2 = H; R3 = H, straight-chain or branched alkyl group, or any of group A; at least one R1 and R3 = one of the group A; the two R1s, two R2s, and two R3s may be identical to or different from one another; R = straight-chain or branched alkyl group]. These compounds are thermally stable, soluble in organic solvents, capable of fabricating thin films by coating method, stable in the air, and are excellent in hole and/or electron field effect mobility (渭FE) and are useful for organic electronic devices such as organic thin film transistor, organic electroluminescent device, display devices, displays, and solar cells. The use of these compounds in the semiconductor layer of organic thin film transistor (TFT), high field effect mobility characteristic is realized. When they are used in the hole or electron transport layer of organic electroluminescent device, high luminescent efficiency is realized. When using in the charge-separation layer, hole transport layer, or electron transport layer of solar cells, high incident photon to current conversion efficiency (IPCE) is realized. Thus, 4,7-dibromobenzo[1,2-c:4,5-c’]bis[1,2,5]thiadiazole was coupled with 2-(tributylstannyl)-5-[3-(trifluoromethoxy)phenyl]thiophene in the presence of dichlorobis(triphenylphosphine)palladium in anhydrous toluene at 100掳 (inner temperature) for 6 h, followed by filtration of the crude product (2.1 g) and sublimation for purification to give 0.25 g compound (II) as green solid. The solubility of II was 0.1 weight% in toluene at 100掳, 0.1 weight% in mesitylene at 80掳, and 0.3 weight% in mesitylene at 130掳. A semiconductor ink containing 0.2 weight% II in Me salicylate was added dropwise into a barrier rib pattern on a polyvinylphenol-melamine thin film (formed on a glass substrate with an aluminum gate electrode), dried at 80掳 to form an organic semiconductor layer on which gold film was vacuum-deposited as source and drain electrode. The fabricated organic TFT had field effect mobility of 6.3 X 10-1 cm2/Vs. The experimental process involved the reaction of 5-Bromo-2-iodobenzotrifluoride(cas: 364-12-5).Quality Control of 5-Bromo-2-iodobenzotrifluoride

The Article related to organic thin film transistor benzobisthiadiazole semiconductor layer, benzobisthiadiazole preparation solar cell organic electroluminescent device, Heterocyclic Compounds (More Than One Hetero Atom): Other 5-Membered Rings, Two Or More Hetero Atoms and other aspects.Quality Control of 5-Bromo-2-iodobenzotrifluoride

Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com

On December 10, 2015, Grammenos, Wassilios; Boudet, Nadege; Mueller, Bernd; Escribano Cuesta, Ana; Lohmann, Jan Klaas; Grote, Thomas; Craig, Ian Robert; Fehr, Marcus; Quintero Palomar, Maria Angelica; Lauterwasser, Erica May Wilson; Kretschmer, Manuel published a patent.Product Details of 364-12-5 The title of the patent was Preparation of substituted [1,2,4]triazole compounds as agrochemical fungicides. And the patent contained the following:

The present invention relates to compounds of the formula I [R1 = each (un)substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, or C3-6 cycloalkyl; R2 = H or each (un)substituted C1-4 alkyl, C2-4 alkenyl, or C2-4 alkynyl; R3 = H, halogen, cyano, or each (un)substituted C1-4 alkyl, C1-4 alkoxy, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, or S(O)p(C1-4 alkyl), wherein p = 0-2; R4, R5, R6 = independently H, halogen, or each (un)substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-4 alkoxy, C3-6 cycloalkyl, C3-6 cycloalkenyl, C3-6 cycloalkyl-C1-4 alkyl, -N(Ra)2, C3-6 halogencycloalkyl, aryl, or aryloxy; R4 and R5 together are =O, and R6 is as defined above; R4 and R5 together are :C(Ra)2, and R6 is as defined above and Ra is as defined below; or R4 and R5 together form a carbocycle or heterocycle, and R6 is as defined above; Ra = independently halogen, OH, cyano, C1-4 alkyl, C1-4 halogenalkyl, C3-6 cycloalkyl, C3-6 halogencycloalkyl, C1-4 alkoxy, C1-4 halogenalkoxy, or and Si(C1-4 alkyl)3; X = O, S(O)n, wherein n = 0-2, or (un)substituted NH] and the N-oxides and the agriculturally acceptable salts thereof. These compounds have an improved activity and/or a broader activity spectrum against phytopathogenic harmful fungi and are useful for combating phytopathogenic fungi in plants or seeds. Thus, a mixture of 3-chloro-4-[1-cyclopropyl-1-hydroxy-2-(1,2,4-triazol-1-yl)ethyl]phenol 500, Cs2CO3 870, and dibromotetrafluoroethane 930 mg in 5 mL DMSO was heated to 50掳 for 3 days to give, after workup, 1-[4-(2-bromo-1,1,2,2-tetrafluoroethoxy)-2-chlorophenyl]-1-cyclopropyl-2-(1H-1,2,4-triazol-1-yl)ethanol (II) as a yellow oil. One invention compound (III) completely controlled the growth of gray mold Botrytis cinerea at 31 ppm, rice blast Pyricuiaria oryzae at 31 ppm, and leaf blotch on wheat caused by Septoria tritici at 8 ppm. The experimental process involved the reaction of 5-Bromo-2-iodobenzotrifluoride(cas: 364-12-5).Product Details of 364-12-5

The Article related to triazole preparation agrochem fungicide, phenylcyclopropyltriazolylethanol preparation agrochem fungicide, Heterocyclic Compounds (More Than One Hetero Atom): Other 5-Membered Rings, Two Or More Hetero Atoms and other aspects.Product Details of 364-12-5

Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com

On September 5, 2012, Zhou, Fengtao; Guo, Jiajia; Liu, Jianguang; Ding, Ke; Yu, Shouyun; Cai, Qian published an article.Recommanded Product: 70931-59-8 The title of the article was Copper-Catalyzed Desymmetric Intramolecular Ullmann C-N Coupling: An Enantioselective Preparation of Indolines. And the article contained the following:

The first highly enantioselective copper-catalyzed intramol. Ullmann C-N coupling reaction has been developed. The asym. desymmetrization of 1,3-bis(2-iodoaryl)propan-2-amines catalyzed by CuI/(R)-BINOL-derived ligands led to the enantioselective formation of indolines in high yields and excellent enantiomeric excesses. This method was also applied to the formation of 1,2,3,4-tetrahydroquinolines in high yields and excellent enantioselectivity. The experimental process involved the reaction of 1-(Bromomethyl)-4-fluoro-2-iodobenzene(cas: 70931-59-8).Recommanded Product: 70931-59-8

The Article related to iodoarylpropanamine iodoarylpentanamine copper binol catalyzed desymmetrization intramol ullmann coupling, indoline tetrahydroquinoline stereoselective preparation, Heterocyclic Compounds (One Hetero Atom): Indoles, Indolizines, Carbazoles, and Other Arenopyrroles and other aspects.Recommanded Product: 70931-59-8

Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com

On February 21, 2013, Dineen, Thomas; Marx, Isaac E.; Nguyen, Hanh Nho; Weiss, Matthew published a patent.Recommanded Product: 5-Bromo-2-iodobenzotrifluoride The title of the patent was Preparation of indolesulfoamide derivatives as sodium channel inhibitors useful in the treatment of pain disorders. And the patent contained the following:

The invention relates to indolesulfoamide derivatives of formula I and II; pharmaceutical composition containing them; and their preparation and use as sodium channel inhibitors for the treatment of pain disorders. Indolesulfoamide derivatives of formula I and II, wherein X1, X2 and X3 are independently CH, Chalo, CC1-6 alkyl, COC1-6 alkyl, CCN and N; R1 is (un)substituted 5- and 6-membered (hetero)aryl and (hetero)cycloalkyl; R2 is (un)substituted 5- to 10-membered (hetero)cycloalkyl and (hetero)aryl; R3 is H, C1-6 alkyl, COC1-6 alkyl, CO2C1-6 alkyl and SO2C1-6 alkyl; R4 is H and C1-6 alkyl; and their pharmaceutically acceptable salt, are claimed. Example compound III was prepared by cross coupling of 3-bromo-N-(2,4-dimethoxybenzyl)-N-(1,2,4-thiadiazol-5-yl)-1H-indole-6-sulfonamide with (4-chloro-2-(1-methyl-1H-pyrazol-5-yl)phenyl)boronic acid to afford 3-(4-chloro-2-(1-methyl-1H-pyrazol-5-yl)phenyl)-N-(2,4-dimethoxybenzyl)-N-(1,2,4-thiadiazol-5-yl)-1H-indole-6-sulfonamide, which underwent debenzylation to give compound III. All the example compounds were evaluated for their sodium channel inhibitory activity. From the assay, it was determined that example compound III exhibited IC50 value of 0.445 渭M and > 10.0 渭M against Nav 1.7 and Nav 1.5 resp. The experimental process involved the reaction of 5-Bromo-2-iodobenzotrifluoride(cas: 364-12-5).Recommanded Product: 5-Bromo-2-iodobenzotrifluoride

The Article related to indolesulfoamide preparation sodium channel inhibitor treatment pain, Heterocyclic Compounds (One Hetero Atom): Indoles, Indolizines, Carbazoles, and Other Arenopyrroles and other aspects.Recommanded Product: 5-Bromo-2-iodobenzotrifluoride

Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com

On July 31, 2003, Egbertson, Melissa; Melamed, Jeffrey Y.; Langford, H. Marie; Young, Steven D. published a patent.Application In Synthesis of 1-(Bromomethyl)-4-fluoro-2-iodobenzene The title of the patent was Preparation of hydroxynaphthyridinone carboxamides useful as HIV integrase inhibitors. And the patent contained the following:

Hydroxynaphthyridinone carboxamides (shown as I; variables defined below; e.g. N-(4-fluorobenzyl)-4-hydroxy-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide) are described as inhibitors of HIV integrase and inhibitors of HIV replication. These compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds were employed against HIV infection and AIDS as compounds per se or as pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions (one example given), optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described. Although the methods of preparation are not claimed, 27 example preparations of I are included; all have IC50’s <0.5 渭M in a HIV integrase assay and all have IC95's <5 渭M in an assay for inhibition of HIV replication. For I: L = linker connecting the C atom of the Ph ring to the N of the -NH- moiety = single bond, -(C1-6 alkyl)- (un)substituted with -C(O)N(RaRb), -(C0-3 alkyl)-C:C-(C1-3-alkyl)-, -(C0-3 alkyl)-C顚咰-(C1-3-alkyl)-, or -(C0-6 alkyl)-(C3-6 cycloalkyl)-(C0-6-alkyl)-. R1a, R1b, and R1c = H, halogen, -C1-6 alkyl, or -C1-6 haloalkyl; R2a and R2b = H, -C1-6 (un)substituted alkyl, -O-C1-6 (un)substituted alkyl, -OH, halo, -NO2, -CN, -C(O)Ra, -CO2Ra, -S(O)nRa, -SO2N(RaRb), -N(RaRb), -C(O)N(RaRb), -N(Ra)SO2Rb, -OC(O)N(RaRb), -N(Ra)C(O)N(RaRb), -N(Ra)-C1-6-alkyl-C(O)N(RaRb), -N(Ra)-C(O)-C1-6 alkyl-N(RaRb), -N(Ra)C(O)-C(O)N(RaRb), -OCO2Ra, -N(Ra)-SO2N(RaRb), -N(Ra)-SO2-C1-6 alkyl-N(RaRb), -N(Ra)C(O)Rb, -N(Ra)CO2Rb, -S-C1-6 alkyl-C(O)N(RaRb),or -N(SO2Ra)-C1-6 alkyl-C(O)N(RaRb). R3 = H, -C1-6-(un)substituted alkyl, -S(O)nRa, -SO2N(RaRb), -C2-6 (un)substituted alkenyl, -C2-5 (un)substituted alkynyl, -Rk, -S(O)n-C1-6 alkyl-Rk, -N(Ra)C(O)-Rk, or -N(Ra)C(O)-C1-6 alkyl-Rk; each of R4 and R5 = H, -C1-6 (un)substituted alkyl, -SO2N(RaRb), or -C1-6 alkyl-Rm; each Ra and Rb = H, -C1-6 alkyl, or -C3-8 cycloalkyl; Rk is a carbocycle or a heterocycle; each Rm = a carbocycle or a heterocycle; each n = 0, 1 or 2; addnl. details including provisos are given in the claims. The experimental process involved the reaction of 1-(Bromomethyl)-4-fluoro-2-iodobenzene(cas: 70931-59-8).Application In Synthesis of 1-(Bromomethyl)-4-fluoro-2-iodobenzene

The Article related to hydroxynaphthyridinone carboxamide preparation hiv integrase inhibitor, aids drug hydroxynaphthyridinone carboxamide preparation hiv integrase inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Application In Synthesis of 1-(Bromomethyl)-4-fluoro-2-iodobenzene

Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com

Liu, Can; Zhu, Xianjin; Han, Yongzhen; Yang, Haijun; Zhu, Changjin; Fu, Hua published an article in 2019, the title of the article was Superbase-promoted selective carbon-carbon bond cleavage driven by aromatization.Application of 70931-59-8 And the article contains the following content:

A novel selective carbon-carbon single bond cleavage has been disclosed through the copper-catalyzed reaction of 1-alkyl-3-alkylindolin-2-imine hydrochlorides I鈥Cl (R1 = 7-CH3, 5-OCH3, 5-Cl, etc.; R2 = CH3, CH2C6H5, CH2CH=CH2, etc.; R3 = C2H5, CH2C6H5, 4-ClC6H4CH2, etc.) with substituted 1-(bromomethyl)-2-iodobenzenes R4-2-(X)C6H3CH2Br (R4 = H, 5-OCH3, 4-F, 5-F, 5-Cl; X = I, Br) leading to fused N-heterocycles II (R5 = 7-CH3, 9-OCH3, 9-Cl, etc.; R6 = 2-OCH3, 3-F, 2-F, 2-Cl). Mechanistic studies showed that the intrinsic drive of aromatization and the action of the superbase derived from sodium tert-butoxide and dimethylsulfoxide were the key factors leading to the carbon-carbon single bond cleavage. Furthermore, the obtained N-heterocycles are indoloquinoline derivatives II with wide biol. activities. The experimental process involved the reaction of 1-(Bromomethyl)-4-fluoro-2-iodobenzene(cas: 70931-59-8).Application of 70931-59-8

The Article related to indoloquinoline preparation chemoselective, alkyl alkylindolin imine hydrochloride bromomethyl iodobenzene aromatization copper catalyst, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Application of 70931-59-8

Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com